Get the Stockscreener App
27.72
0.54%
0.15
Oculis Holding Ag stock is traded at $27.72, with a volume of 364.82K.
It is up +0.54% in the last 24 hours and up +5.12% over the past month.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.
See More
Previous Close:
$27.57
Open:
$27.57
24h Volume:
364.82K
Relative Volume:
1.56
Market Cap:
$1.60B
Revenue:
-
Net Income/Loss:
$-75.28M
P/E Ratio:
-13.89
EPS:
-1.9957
Net Cash Flow:
$-57.45M
1W Performance:
-6.22%
1M Performance:
+5.12%
6M Performance:
+61.54%
1Y Performance:
+54.09%
1-Day Range:
$26.91
$28.70
1-Week Range:
$26.91
$30.00
52-Week Range:
$14.00
$30.68
Oculis Holding Ag Stock (OCS) Company Profile
Compare OCS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
27.72 | 1.59B | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-25 | Initiated | JP Morgan | Overweight |
| Aug-27-25 | Initiated | Needham | Buy |
| Dec-05-23 | Initiated | Chardan Capital Markets | Buy |
| Oct-05-23 | Initiated | Stifel | Buy |
| Jun-14-23 | Initiated | BofA Securities | Buy |
| Jun-12-23 | Initiated | H.C. Wainwright | Buy |
| Jun-08-23 | Initiated | Robert W. Baird | Outperform |
| May-10-23 | Initiated | Pareto | Buy |
| Apr-28-23 | Initiated | Wedbush | Outperform |
View All
Oculis Holding Ag Stock (OCS) Latest News
Oculis Publishes 2025 Consolidated Financial Statements - GlobeNewswire
Why Oculis (OCS) Is Down 6.2% After New Equity Programs To Fund Late-Stage Trials - simplywall.st
Oculis Holding AG renews $100 million at-the-market offering program - Investing.com Australia
Stifel raises Oculis stock price target to $50 on pipeline progress - Investing.com
Oculis Holding AG renews $100 million at-the-market offering program By Investing.com - Investing.com South Africa
Oculis Files 2025 Financials and Renews $100 Million ATM Program - TipRanks
Oculis Holding (NASDAQ: OCS) widens loss but ends 2025 with strong cash and $100m ATM capacity - Stock Titan
Oculis price target raised to $44 from $42 at H.C. Wainwright - TipRanks
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewswire
Oculis (NASDAQ: OCS) 2025 20-F details losses, cash and trials - Stock Titan
HC Wainwright Issues Positive Forecast for Oculis (NASDAQ:OCS) Stock Price - MarketBeat
Oculis (NASDAQ:OCS) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - MarketBeat
Chardan Raises Price Target on Oculis Holding to $53 From $51, Keeps Buy Rating - marketscreener.com
Oculis Holding's Q4 Net Loss Narrows; Plans Phase 3 Trial Readouts For OCS-01 In Q2,2026 - Nasdaq
Oculis Reports Q4 and Full-Year 2025 Results, Shares Update - InvisionMag.com
Oculis Posts 2025 Results, Extends Cash Runway and Advances Late-Stage Ophthalmology Pipeline - TipRanks
Oculis Holding AG (OCS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
[6-K] Oculis Holding AG Current Report (Foreign Issuer) | OCS SEC FilingForm 6-K - Stock Titan
Eye drug firm Oculis eyes 3 major 2026 vision milestones after $119M loss - Stock Titan
Oculis (OCS) to Release Quarterly Earnings on Tuesday - MarketBeat
Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Earnings To Watch: Oculis Holding AG (OCS) Reports Q4 2025 Resul - GuruFocus
OCS Earnings History & Surprises | EPS & Revenue Results | OCULIS HOLDING AG (NASDAQ:OCS) - ChartMill
Discipline and Rules-Based Execution in OCS Response - Stock Traders Daily
Oculis Holding AG expected to post a loss of 42 rappen a shareEarnings Preview - TradingView
Oculis Holding AG (OCS) Stock Analysis: A Promising 52.55% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Oculis (NASDAQ:OCS) Sets New 12-Month HighHere's What Happened - MarketBeat
Bull Bear: Can Oculis Holding AG continue delivering strong returnsJuly 2025 Macro Moves & Community Trade Idea Sharing Platform - baoquankhu1.vn
Big Picture: Will Oculis Holding AG benefit from green energy policiesTrade Risk Report & Fast Entry Momentum Alerts - baoquankhu1.vn
Will Oculis Holding AG benefit from green energy policiesMarket Activity Recap & Fast Gain Stock Tips - mfd.ru
Oculis Holding AG (OCS) Investor Outlook: Analyst Ratings Signal a 59.98% Upside Potential - DirectorsTalk Interviews
Fund Flows: Whats the profit margin of Oculis Holding AG Equity Warrant2025 Top Decliners & Low Risk High Win Rate Picks - baoquankhu1.vn
Oculis (NASDAQ:OCS) Hits New 1-Year HighHere's Why - MarketBeat
Aug EndMonth: Can Oculis Holding AG beat the S P 5002025 Major Catalysts & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated - Yahoo Finance UK
Behavioral Patterns of OCS and Institutional Flows - Stock Traders Daily
Oculis Appoints Katie Kazem as Chief Legal Officer - InvisionMag.com
Oculis Appoints Katie Kazem as Chief Legal Officer to Strengthen Leadership Team - Quiver Quantitative
Why Oculis Holding AG stock remains undervaluedJuly 2025 Closing Moves & Growth Focused Stock Reports - mfd.ru
Earnings Miss: Should you avoid Oculis Holding AG Equity Warrant stock right now - baoquankhu1.vn
Can Oculis Holding AG Equity Warrant stock surprise with earnings upsideJuly 2025 Setups & Stock Portfolio Risk Management - mfd.ru
How does Oculis Holding AG compare to its peersVolume Spike & Capital Efficiency Focused Ideas - mfd.ru
Published on: 2026-02-15 01:23:26 - mfd.ru
Oculis Holding AG (OCS) Stock Analysis: A 61% Potential Upside In The Biotech Arena - DirectorsTalk Interviews
What’s the outlook for Oculis Holding AG’s sector2025 Technical Overview & Precise Swing Trade Alerts - mfd.ru
OCS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Market Wrap: Whats next for Oculis Holding AG stock2025 Institutional Moves & Precise Swing Trade Alerts - baoquankhu1.vn
Why Oculis Holding AG stock is favored by top institutionsPortfolio Profit Report & Daily Growth Stock Tips - mfd.ru
Will Oculis Holding AG benefit from rate cutsJuly 2025 Movers & Verified Momentum Stock Ideas - mfd.ru
Is Oculis Holding AG Equity Warrant attractive for institutional investorsTrade Signal Summary & Weekly Stock Performance Updates - mfd.ru
Aug Selloffs: Can Oculis Holding AG maintain sales growth2025 Technical Patterns & Safe Capital Growth Stock Tips - baoquankhu1.vn
Oculis Holding Ag Stock (OCS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):